Giménez, Marga
Khunti, Kamlesh
Matsuhisa, Munehide
Chenji, Suresh
Syring, Kristen
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 5 June 2023
Accepted: 21 August 2023
First Online: 14 September 2023
Declarations
:
: Marga Giménez has received lecturing and consulting fees from Eli Lilly and Company, Medtronic Inc., Novo Nordisk, Sanofi-Aventis, and MSD. Munehide Matsuhisa has received honoraria from Eli Lilly Japan, Sanofi, Novo Nordisk Pharma, Abbott Japan, Sumitomo Pharma, Kyowa Kirin, Nippon Boehringer Ingelheim, and Orizuru Therapeutics; research funding from Novo Nordisk Pharma, Sysmex and Nissui. Kamlesh Khunti has acted as a consultant, speaker or received grants for investigator-initiated studies for Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, MSD, Napp, Novartis, Novo Nordisk, and Sanofi-Aventis. Suresh Chenji, Kristen Syring, and Yu Yan are employees and shareholders of Eli Lilly and Company.
: This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.